Stoke Therapeutics Files 8-K Report
Ticker: STOK · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Stoke Therapeutics filed an 8-K, likely containing financial updates or other material disclosures.
AI Summary
On June 4, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates Stoke Therapeutics is providing updated information to the SEC, which could include financial updates or disclosures of material events relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of negative news or significant financial changes.
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- June 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38938 (identifier) — Commission File Number
- 47-1144582 (identifier) — IRS Employer Identification No.
- 45 Wiggins Ave (address) — Principal Executive Offices
- Bedford, Massachusetts (location) — Principal Executive Offices Location
- 01730 (zip_code) — Principal Executive Offices Zip Code
- (781) 430-8200 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Stoke Therapeutics, Inc.?
The filing is a Current Report (Form 8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated June 4, 2025.
What is Stoke Therapeutics, Inc.'s state of incorporation and commission file number?
Stoke Therapeutics, Inc. is incorporated in Delaware and its commission file number is 001-38938.
Where are Stoke Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts, 01730.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (781) 430-8200.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Stoke Therapeutics, Inc. (STOK).